Mestag Appoints Dr. Matthew Sleeman as Chief Scientific Officer
Portfolio - People | Mar 04, 2025 | SV Health Investors, LLC
Mestag Therapeutics has appointed Dr. Matthew Sleeman as its new Chief Scientific Officer. Dr. Sleeman is an accomplished R&D leader with over two decades of experience in immunology and cancer, having led the development of multiple FDA-approved monoclonal antibodies. He joins Mestag from Regeneron, where he was Vice President of Research and Head of the Therapeutic Focus Area on Immunology & Inflammation. At Mestag, Dr. Sleeman will focus on advancing the company's pipeline of antibodies aimed at treating inflammatory diseases and cancer. Mestag, headquartered in Cambridge, UK, is particularly noted for its work in fibroblast immunology and novel antibody therapies, including collaborations with MSD and Johnson & Johnson.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United Kingdom – Mestag Therapeutics is headquartered in Cambridge, UK, which is a key hub for biotechnology and pharma innovation.
- United States – The collaboration with American companies such as MSD and Dr. Sleeman's previous role at the US-based Regeneron ties the operations to this geography.
Industry
- Biotechnology – Mestag Therapeutics operates in the biotechnology sector, focusing on the development of antibody-based therapies for cancer and inflammatory diseases.
- Pharmaceuticals – The involvement of firms like Regeneron and Johnson & Johnson highlights the pharmaceutical industry's role in advancing therapeutic R&D and collaborations.
Financials
- $1.3 billion – The acquisition value of Cambridge Antibody Technology by AstraZeneca in 2006, mentioned in Dr. Sleeman's career history.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mestag Therapeutics | Company | Target | A biotech company focused on fibroblast immunology for treating inflammatory diseases and cancer. |
| Dr. Matthew Sleeman | Person | New Chief Scientific Officer | Appointed as Chief Scientific Officer at Mestag Therapeutics with extensive R&D experience. |
| SV Health Investors | Company | Private Equity Firm | Founder of Mestag and an influential life sciences investment firm. |
| Regeneron | Company | Former Employer | Previous employer of Dr. Matthew Sleeman, where he led significant R&D efforts. |
| MSD | Company | Collaborative Partner | Engaged in a research collaboration with Mestag to identify novel targets for inflammatory diseases. |
| Johnson & Johnson Innovation JJDC, Inc. | Company | Investor | Investment entity supporting Mestag Therapeutics. |